High dose chemotherapy and autologous bone marrow transplantation in refractory hodgkinʹs disease

Philip, T, Dumont, J, Teillet, F, Maraninchi, D, Gorin, NC, Kuentz, M, Harousseau, JL, Marty, M, Pinkerton, R and Herve, P (1986) High dose chemotherapy and autologous bone marrow transplantation in refractory hodgkinʹs disease. British Journal of Cancer, 53 6: 737-742. doi:10.1038/bjc.1986.127


Author Philip, T
Dumont, J
Teillet, F
Maraninchi, D
Gorin, NC
Kuentz, M
Harousseau, JL
Marty, M
Pinkerton, R
Herve, P
Title High dose chemotherapy and autologous bone marrow transplantation in refractory hodgkinʹs disease
Journal name British Journal of Cancer   Check publisher's open access policy
ISSN 1532-1827
Publication date 1986-01-01
Year available 1986
Sub-type Article (original research)
DOI 10.1038/bjc.1986.127
Open Access Status Not yet assessed
Volume 53
Issue 6
Start page 737
End page 742
Total pages 67
Publisher CHURCHILL LIVINGSTONE
Language eng
Subject 1306 Cancer Research
2730 Oncology
Abstract Seventeen patients with Hodgkin's disease (HD) were treated with high-dose chemotherapy followed by autologous bone marrow transplantation (ABMT). Eleven patients were resistant to initial therapy. Three patients had relapsed and were still responders to second or third line therapy. Three patients had relapsed but were progressing under second or third line therapy. Pre-ABMT chemotherapy included high dose cyclophosphamide in all patients (50 mg Kg–1 day–1 bolus for 4 days), most often associated with BCNU or CCNU, aracytine and 6 thioguanine. Four patients received additional TBI (10 Gy). In 9 patients complete remission (CR) was achieved, 4 failed to respond and 4 cases were not evaluable due to early death. Among CR patients, 2 died from late toxicity, 4 relapsed between the 2nd and 5th months, but 3 patients remain in CR, off therapy at 25+, 43+, and 66 + months, including 1/11 initially resistant and 2/6 who had relapsed. There were 9 treatment related deaths: 6 due to infection, cardiac failure and 2 multiorgan failure. The high complete response rate in these heavily pretreated patients suggests that there may be an indication for high dose therapy earlier in resistant HD. Moreover under such conditions, treatment related morbidity would be expected to be lower.
Keyword Oncology
Oncology
ONCOLOGY
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collection: ResearcherID Downloads - Archived
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 70 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 46 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 09 Jul 2016, 04:04:34 EST by System User